Market Research Report on Hemophilia Drugs in China

Hemophilia is a rare genetic disorder that reduces the body's clotting function, leading to prolonged bleeding time after injury, making patients prone to bruising and increasing the risk of joint or brain hemorrhage. There is a significant unmet clinical need for hemophilia in China. For this reason, based on research into the market, Frost & Sullivan (Frost & Sullivan) has released a related industry report.